PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells

• Published in: International journal of biological sciences 2021-01, Vol.17 (1), p.188-203
• Main Authors: Liu, Wei, Wang, Chunyu, Wang, Shengli, Zeng, Kai, Wei, Shan, Sun, Ning, Sun, Ge, Wang, Manlin, Zou, Renlong, Liu, Wensu, Lin, Lin, Song, Huijuan, Jin, Zining, Zhao, Yue
• Format: Article
• Language: English
• Subjects: Androgen receptors; Androgens; Antibodies; Castration; Cell growth; Cell Line, Tumor; Depletion; Experiments; Gene Expression Regulation, Neoplastic; Genes; Genomics; Humans; Jumonji Domain-Containing Histone Demethylases - metabolism; Ligands; Male; mRNA; mRNA processing; Plasmids; Post-transcription; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - metabolism; Reagents; Receptors; Receptors, Androgen - genetics; Receptors, Androgen - metabolism; Regulatory sequences; Research Paper; RNA Splicing Factors - metabolism; Transcription Factors - metabolism; Transcriptional Activation; Tumor cell lines; Tumors; Xenografts; Xenotransplantation
• ISSN: 1449-2288; 1449-2288
• DOI: 10.7150/ijbs.50810

Androgen receptor (AR) and its variants play vital roles in development and progression of prostate cancer. To clarify the mechanisms involved in the enhancement of their actions would be crucial for understanding the process in prostate cancer and castration-resistant prostate cancer transformation. Here, we provided the evidence to show that pre-mRNA processing factor 6 (PRPF6) acts as a key regulator for action of both AR full length (AR-FL) and AR variant 7 (AR-V7), thereby participating in the enhancement of AR-FL and AR-V7-induced transactivation in prostate cancer. In addition, PRPF6 is recruited to -regulatory elements in AR target genes and associates with JMJD1A to enhance AR-induced transactivation. PRPF6 also promotes expression of AR-FL and AR-V7. Moreover, PRPF6 depletion reduces tumor growth in prostate cancer-derived cell lines and results in significant suppression of xenograft tumors even under castration condition in mouse model. Furthermore, PRPF6 is obviously highly expressed in human prostate cancer samples. Collectively, our results suggest PRPF6 is involved in enhancement of oncogenic AR signaling, which support a previously unknown role of PRPF6 during progression of prostate cancer and castration-resistant prostate cancers.